Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-05-15, Stock:NVS, The news for the past five days is as follows:
2019-05-08: NEWS1: Novartis buys Takeda's dry eye drug for $3.4 bln.NEWS2: Novartis buys dry-eye drug Xiidra rights from Takeda for $3.4 billion.NEWS3: Novartis buys Takeda's dry eye drug for $3.4 bln.NEWS4: Aduro (ADRO) Q1 Earnings and Revenues Fall Shy of Estimates.NEWS5: Aduro (ADRO) Q1 Earnings and Revenues Fall Shy of Estimates.NEWS6: Novartis confident of Zolgensma supply, calls $2 million price "speculation".NEWS7: Aduro (ADRO) Q1 Earnings and Revenues Fall Shy of Estimates.NEWS8: Validea Peter Lynch Strategy Daily Upgrade Report - 5/8/2019.NEWS9: Validea Peter Lynch Strategy Daily Upgrade Report - 5/8/2019.
2019-05-09: NEWS1: Top Trending: Chevron backs out of Anadarko deal, Novartis purchases Takeda Eye, Walmart manager salaries.NEWS2: Novartis to Buy Takeda's Eye Drug in $5.3 Billion Deal.NEWS3: Novartis’s $5.3 Billion Eye Disease Deal Adds Cash for Bigger Bets .NEWS4: Codexis Bags Novartis as Software Customer, Stays Course in First Quarter.NEWS5: The Daily Biotech Pulse: Novartis Goes Shopping, Mixed Trial Results For Provention Bio, 4 Stocks To Debut.NEWS6: Stocks making the biggest moves premarket: Disney, Intel, Etsy, Fox Corp, Costco, Novartis & more.NEWS7: Stocks making the biggest moves premarket: Disney, Intel, Etsy, Fox Corp, Costco, Novartis & more.NEWS8: Novartis buys dry eye drug from Takeda for up to $5.3 billion.NEWS9: Novartis to Buy Takeda Eye Drug Assets in $5.3 Billion Deal.NEWS10: Novartis buys dry eye drug from Takeda for up to $5.3 billion.NEWS11: Takeda sheds products, 485 jobs in deals worth $5.7B.NEWS12: Takeda to sell eye drug to Novartis in $5.3bn deal.
2019-05-10: NEWS1: Tilray (TLRY) to Report Q1 Earnings: What's in the Cards?.NEWS2: Tilray (TLRY) to Report Q1 Earnings: What's in the Cards?.NEWS3: Tilray (TLRY) to Report Q1 Earnings: What's in the Cards?.NEWS4: Pharma Stock Roundup: AGN, NVO Report Q1 Earnings, NVS to Buy Takeda's Eye Drug.NEWS5: Pharma Stock Roundup: AGN, NVO Report Q1 Earnings, NVS to Buy Takeda's Eye Drug.NEWS6: Pharma Stock Roundup: AGN, NVO Report Q1 Earnings, NVS to Buy Takeda's Eye Drug.
2019-05-13: NEWS1: Pinterest gets rating, Teva faces major lawsuit, Amazon helps employees start a business.NEWS2: Health Care Sector Update for 05/13/2019: TEVA, NVS, INSY, JNJ, PFE, ABT, MRK, AMGN.NEWS3: Health Care Sector Update for 05/13/2019: TEVA, NVS, INSY, JNJ, PFE, ABT, MRK, AMGN.NEWS4: Teva Plummets Amid Massive Price Fixing Accusations; Other Generic Drugmakers Also Fall.NEWS5: Novartis vows to fight U.S. price-fixing claims against Sandoz unit.NEWS6: Novartis vows to fight U.S. price-fixing claims against Sandoz unit.NEWS7: US generic drug companies hit by price-fixing claims.NEWS8: Fundamentals Of How China Makes Its Money (BABA, PFE).
2019-05-14: NEWS1: Ionis Pharmaceuticals Is 40% of the Way There.NEWS2: Ionis Pharmaceuticals Is 40% of the Way There.NEWS3: Ionis Pharmaceuticals Is 40% of the Way There.NEWS4: Regeneron (REGN) Gets FDA Nod for Eylea Label Expansion.NEWS5: Regeneron (REGN) Gets FDA Nod for Eylea Label Expansion.NEWS6: Generic Drugmakers Face Antitrust Suit Alleging Price Fixing.NEWS7: Generic Drugmakers Face Antitrust Suit Alleging Price Fixing.NEWS8: Generic Drugmakers Face Antitrust Suit Alleging Price Fixing.NEWS9: Regeneron (REGN) Gets FDA Nod for Eylea Label Expansion.

Answer: Rise